Tim Povtak of Asbestos.com reports that a recent study of mesothelioma patients over 80 has revealed the disturbing reality that nearly 70% of the elderly in America being treated for mesothelioma die without receiving any cancer-related treatment that might extend...
Mesothelioma Cancers
Amphera’s MesoPher Mesothelioma Vaccine Shows Promise in Europe
Tim Povtak reports that the MesoPher vaccine combines a patient’s own dendritic immune cells with a specially engineered cell line. It aims to train the immune system to recognize and attack pleural mesothelioma tumor cells. The study is being conduced in five...
Memorial Sloan Kettering Leads Oncology-Focused Investigator Initiate Trial
Memorial Sloan Kettering Cancer Center (MSK) will lead an investigator initiated trial of SELLAS Life Science Group, Inc. (NASDAQ SLS) Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S (GPS), in combination with Bristol-Myers Squibb’s...
CRS207 Development Discontinued Following Failed Phase 2 Keytruda Combo Trial for MPM
The development of CRS207, manufactured by Aduro Biotech, has been discontinued following results from a phase 2 trial evaluating its efficacy in combination with Keytruda (Merck) for previously treated malignant plural mesothelioma. The trial enrolled 10 patients who...
MaxCyte Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial
MaxCyte was formed in 1999. It specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes. Publicly traded under symbol MXCT, MaxCyte is a global cell-based medicines and life sciences company applying its...
Churchill Hospital Oxford Immunotherapy Vaccine Trial Saves Man with Lung Cancer
The UK’s Churchill Hospital Oxford included a 70-year-old male that was diagnosed with mesothelioma of the lung. He was given a year to live at most, according to Karolina Kaminska writing for Express. Professor Angus Dalgleish included the patient in an...
FDA Approves Larotrectinib: Bayer’s Genetics-based Cancer Treatment
A first-of-its-kind cancer drug has just been approved by the U.S. Food and Drug Administration for use in patients with many types of cancer, including malignant mesothelioma. The drug is manufactured by Bayer and is called larotrectinib, though it is sold under the...
BMS’ Nivolumab Shows Promise in Phase 2 for Mesothelioma
Like many other breakthrough cancer medications, nivolumab is a drug that was first developed for more common types of cancer and is only now being tested for use in malignant mesothelioma. The drug is a monoclonal antibody that works as a checkpoint inhibitor: this...
NCI Grants University of Pennsylvania $10.7 Million to Study CAR T-Cell Therapy for Solid Tumors
Healio reports that the National Cancer Institute (NCI) will grant $10.7 million to the University of Pennsylvania’s Abramson Cancer Center to evaluate the use of chimeric antigen receptor T-cell therapy for treatment of solid tumors. It is noted in Healio that...
BAP1 Protein Linked to Tumor Suppression in Kidney, Eye, Bile Duct and Mesothelioma Cancers
Researchers have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor gene in kidney, eye, bile duct, mesothelioma and other cancers by regulating a form of cell death called ferroptosis, opening up a potential new area of therapy research. Lead...